TJ 100

Drug Profile

TJ 100

Alternative Names: Dai-kencho-to; Dai-kenchu-to; TU-100

Latest Information Update: 26 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tsumura
  • Class Anti-inflammatories; Herbal medicines; Laxatives
  • Mechanism of Action Acetylcholine stimulants; Motilin stimulants; Serotonin 3 receptor agonists; Serotonin 4 receptor agonists; Substance P stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Irritable bowel syndrome; Postoperative ileus
  • Phase III Constipation
  • Phase II Crohn's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Sep 2017 TJ 100 is still in phase II development for Irritable bowel syndrome in USA and phase III development for Constipation in Japan (Tsumura pipeline, September 2017)
  • 01 May 2017 Tsumara completes a phase II trial for Postoperative ileus in USA (NCT02232893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top